புதுமையானது சாதனம் நிலை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புதுமையானது சாதனம் நிலை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புதுமையானது சாதனம் நிலை Today - Breaking & Trending Today

EyeYon Medical Receives CE Mark for its EndoArt® Implant to Treat Chronic Corneal Edema

EyeYon Medical Receives CE Mark for its EndoArt® Implant to Treat Chronic Corneal Edema
Font : A-A+
EndoArt® previously received Innovative Device Status by the Chinese NMPA, and Breakthrough Device Designation from the US Food and Drug Administration
TEL AVIV, Israel, June 8, 2021 /PRNewswire/ EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announced today that it has received CE Mark for its EndoArt®, after clinical trials demonstrated safety and efficacy for treating chronic corneal edema.
The CE Mark serves as approval by the European Union (EU) to commercialize EndoArt®, the world s first and only synthetic implant, which replaces the human endothelium that the human body can never regenerate. The current standard of care involves corneal transplantation of human tissue. This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally ....

Comunidad Autonoma De Cataluna , Noord Holland , Nahum Ferera , Amsterdam University Medical Centers , European Union , Drug Administration , Eyeyon Medical , Innovative Device Status , Breakthrough Device Designation , Instituto De Microcirugia Ocular , Ruth Lapid Gortzak , Principal Investigator , Ofer Daphna , Yon Medical , Artificial Endothelial Layer , Binyamin Tjong Alvaresrimon Cohen , Ealth Press Release , காமுனிடட தன்னாட்சி டி கடலுள் , நூற்த் ஹாலண்ட் , ஆம்ஸ்டர்டாம் பல்கலைக்கழகம் மருத்துவ மையங்கள் , ஐரோப்பிய தொழிற்சங்கம் , புதுமையானது சாதனம் நிலை , திருப்புமுனை சாதனம் பதவி , ப்ரிந்ஸிபல் புலனாய்வாளர் , யோன் மருத்துவ ,

Roundup: 'On-the-spot' COVID-19 test receives CE Mark, Thriva launches women's hormones test and more briefs

DACADOO AND DIG ANNOUNCE PARTNERSHIP IN LIFESTYLE INSURANCE
Swiss health tech and insurtech company, dacadoo and Amsterdam-based Digital Insurance Group (DIG) are partnering up to expand their set of insurtech solutions for banking, insurance and brokers.
Using a new quote & buy products set to improve the underwriting process for life operators, the partnership aims to establish real-time pricing of life insurance in the major continents where both companies already have a presence in.
Ingo Weber, CEO & co-founder of DIG said: “Our mission is to give more people access to insurance and make sure they get the protection they need for themselves and their families. We work a lot with innovative insurers and enable them to build disruptive distribution and engagement models including ecosystems. With the solution we’re now building with dacadoo we can even increase the level of personalisation and customer experience.” ....

United Kingdom , New Cross , City Of , Ingo Weber , Elad Walach , Euan Bowen , Sumera Shahaney , King College London , Digital Insurance Group , Edinburgh Business School , European Commission , Watt University , Drug Administration On , Healthcare Products Regulatory Agency , China Center , Amsterdam Based Digital Insurance Group , United Kingdom Medicines , Radiology Partners , Newcross Healthcare , Newcross World , Virtual Shift , Complex Care , Stay Fit Longer , European Active , Assisted Living , Heriot Watt University ,

EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt In China

EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt In China
TEL-AVIV, Israel, April 7, 2021 /PRNewswire/ EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announces today that EndoArt was granted the Innovative Device Status by China s Center for Medical Device Evaluation, the arm of the National Medical Products Administration (NMPA). Following the announcement, the EndoArt became the only ophthalmic device in the world to receive both China s Innovative Device Status and the Breakthrough Device Designation from the U.S. Food and Drug Administration.
The EndoArt is the world s first synthetic implant that enables doctors to treat chronic corneal edema, the main reason for the world s most common organ transplant, with a minimally invasive surgery that erodes the use of human tissue.The EndoArt is designed to replace dysfunctional endothelium in patients awaiting huma ....

Richel Liu , Nahum Ferera , Kostenloser Wertpapierhandel , Yafit Lazar , China National Medical Products Administration , National Medical Products Administration , Drug Administration , China Center , Yon Medical , Innovative Device Status , Medical Device Evaluation , Breakthrough Device Designation , Innovative Device Designation , Rimonci Capital , Venture Capital , Eyeyon Medical , ரிச்செல் லியூ , யபித் லாசர் , சீனா மையம் , யோன் மருத்துவ , புதுமையானது சாதனம் நிலை , மருத்துவ சாதனம் மதிப்பீடு , திருப்புமுனை சாதனம் பதவி , புதுமையானது சாதனம் பதவி , துணிகர மூலதனம் ,

Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation

Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation
Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms Medtronic plc the global leader in medical technology, today announced the first procedures in the investigational device exemption pivotal trial to evaluate the PulseSelect ™ Pulsed Field Ablation System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation . …
Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect ™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fib ....

United States , Fall River , South Lake , Ryan Weispfenning , Allison Kyriagis , Rob Kowal , Arnoldas Giedrimas , Southlake Regional Health Centre In Newmarket , Drug Administration , Southcoast Health , Exchange Commission , Heart Rhythm Society , Ablation Solutions , National Medical Products Administration , Vascular Group At Medtronic , Study Will Determine , Pulsed Electrical Fields , Interrupt Irregular Heart Rhythms , Pulsed Field Ablation , Pulseselect System , Atul Verma , Southlake Regional Health Centre , Cardiac Ablation Solutions , Vascular Group , Breakthrough Device , Innovative Device Status ,